Vaxcyte VAX-24 Phase 1/2 meets all endpoints; 2.2mcg dose advances to Phase 3

Vaxcyte, Inc.

VAX-24 safety profile similar to Prevnar 20 at all doses; no related SAEs or chronic illnesses.
All 24 serotypes met/exceeded regulatory immunogenicity standards at 2.2mcg dose.
Of 20 serotypes common with PCV20, 16 showed higher OPA immune responses; 4 reached statistical significance.
All 4 unique serotypes (2, 9N, 17F, 20B) exceeded standard superiority criteria at all doses.
Milestones: Phase 3 adult data expected 2025; infant Phase 2 initiation in H1 2023; VAX-XP (31-valent) IND in H2 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.